JOIN

ACIP Meeting Report – Jan 5th 2022

Following the FDA update on the Emergency Use Authorization (EUA) Fact Sheet for Pfizer-BioNTech COVID-19 vaccine on January 3rd 2022, Advisory Committee on Immunization Practices (ACIP) met to review safety data on this vaccine in children
and adolescents for the purpose of voting on a recommendation to extend use of the booster dose to 12-15yo adolescents.

To view the CDC ACIP Meeting Report from January 5th 2022, see below.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

More SAFETY TEMPLATES

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023

Modified Vaccinia Ankara (MVA) vaccine platform: standardized template for collection of key information for risk/benefit assessment

October 4, 2023

Medigen COVID-19 protein vaccine: standardized template with key considerations for a benefit/risk assessment

April 6, 2023

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

August 19, 2022
View All

More Posts

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.